Cohance Lifesciences Limited (COHANCE) Q4 2026 Earnings Call Transcript

Ladies and gentlemen, good day and welcome to the Q4 and FY26 earnings conference call of Cohan's Life Sciences Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Cinderella Karvalo. Thank you, and over to you, ma'am.

Thanks, Darwin. Good evening and good morning, everyone. And thank you for joining Kohans Life Sciences, Cotter 4 and F526 Earnings Call. Today, we welcome our Executive Chairman and Group CEO, Mr. Uma Gora, on his first Earnings Call with Kohans. Joining me today are Mr. Yan, our CEO of AMA. Before we begin, I would like to remind you that today discussion may include forward-looking statements. With that, I will hand it over to Omar for his opening remarks.

Thank you, Cinderella, and good evening to everyone on the call. I am very happy to be here. Having spent over three decades in this industry, I'm excited to be part of a platform that is anchored in science with capabilities such as ADCs and oligonucleotides, which are well differentiated and hard to replicate in terms of a value offering. Kohans is well positioned to be such a platform. It is also important to acknowledge the team behind the platform, the colleagues on this call, along with the broader leadership group, and our 640 scientists who bring this science to life every day represent a strong foundation. My immediate priority over the next few months will be to spend time with our teams, customers, and sites. By the end of this fiscal year, the intent is to create a strategic blueprint for growth and sustainable value creation. Over the next few years, we intend to focus Kohans' capabilities and science on the predictability of delivery, backed by our strong quality and systems, a deep talent pool, and a pipeline that matters to our partners and our patients. With that, I will hand it over to Jan.

Thank you, Eumank, and good evening, everyone. The pharmacy GMO business reported revenue of 8.89 billion rupees for FY26. Adjusting for the stocking impact in the two large commercial molecules, the business delivered an underlying growth of early single digits. Commercial products contributed more than 70% of stand-alone pharma CDMO revenues in FY26. Overall, we have more than 140 active projects across the pharma CDMO's stand-alone portfolio, covering both development and commercial programs. On small molecules, while FY26 was impacted, By customer inventory adjustments, order phasing, and slower reloads, engagement with customers for both the large commercial products currently under the stocking continues to remain steady. We added one new phase 3 lateral program in small molecules with a large innovator, along with one program each in ADC and oligonucleotide advancing into phase 3. With two programs progressing towards commercialization, the total Phase III pipeline now stands at 10 programs. Within the Phase III pipeline, one program is under priority review, and another is awaiting clinical data readouts expected in calendar year 26. Of the two programs that recently entered commercialization, we have recently received orders for one involving four intermediates, with the other that is also expected to contribute during FY27. Reload conversion remains quite high, above 90%, and new business conversion with innovative pharma and biotech customers continue to be happening. On ADCs, customer interest continues in payload linker programs. In FY26, we have filed three payload DMFs, and many additional payload linker filings are on the way. We are also seeing traction in newer payload platforms, including Exatecan linked opportunities. During the year, we initiated work on adjacent-tailored platforms based on customer inquiries. At NGBIO, we continue to expand our integrated ADC capabilities. The platform has successfully completed the first bioconjugation campaign during Q426. CGMP. Expansion work of $10 million capex at the ENGIE Bio U.S. facility is progressing to support future scalars. Phase 2 requirements and nation readiness. In oligonucleotide segment, through the Sapana platform, we have received a follow-on purchase order. The CGMP oligonucleotide building block facility is under validation. Several customer qualifications and higher complexity RFPs are progressing. During the last few months, we completed more than 20-plus audits and customer visits from large and mid-sized innovative pharma and biotech customers. Several of these included senior customer teams visiting our facilities. To summarize, FY26 revenues were impacted by restocking, customer inventory adjustments, and delayed reloads. However, RFQ activity, customer audits, late-stage programs, and pipeline building work continues. The focus for FY27 is execution, auto-conversion. And delivery visibility. With that, I will hand over to Gunjan.

Thank you, Jan, and good evening, everyone. The API Plus business reported revenues of 10.88 billion rupees in FY26, reflecting a decline of 8% year on year. The software performance was due to product-specific factors, shipment delays, and temporary disruptions at the Nacharam formulation site. Hi, everyone. Performance through the second half improved sequentially as the supply execution stabilized, the customer engagement strengthened, and the order conversion improved across key markets. In APIs, the portfolio continues to remain broad and differentiated. Our top 15 leadership products contribute around half of the API revenues, and eight of our top 10 molecules continue to hold leadership positions. The business remains supported by niche, small-to-mid-volume products, diversified customer relationships, cost competitiveness, and backward integration capabilities. During the year, the demand across therapies remained largely stable, with growth primarily volume-dead. While select mature molecules experienced pricing pressure, this was substantially mitigated through higher volumes, operating efficiency, portfolio expansion, and focused cost actions. Importantly, the challenges during FY26 were concentrated around a limited set of products and customer-specific situations, rather than deflecting any structural weakness in the portfolio. As highlighted over the course of the year, we have continued to strengthen our development pipeline and diversify the revenue base. During FY26, we completed 10 new findings and validated 6 more new products. We also advanced multiple new customer engagements, including lifecycle management opportunities with European customers, which are expected to scale progressively over the medium term. The breadth of the pipeline today is materially stronger than it was a year ago and provides a broader platform for future growth. On the formulation side, revenues were impacted by approximately 610 million rupees during FY26. Due to the temporary disruptions at our Nacharam site and the associated shipment difference, production and U.S. supplies have since resumed, and remediation actions implemented over the past several months are strengthening quality and operating systems at the site. While utilization levels are still normalizing, customer engagement and order visibility have steadily improved. In parallel, we have continued to actively manage supply chain continuity through alternate site strategies and closer customer coordination. We expect further normalization over the coming quarters as execution stabilizes and the order book progressively converts into shipment. On the business front, we supported five launches during the year while additional two launches moved into the next quarter based on customer time. Further, there are a few very interesting and differentiated opportunities in our formulation business that are shaping up. Most of these are leveraging our integrated API and FDF base. Overall, API Plus enters FY27 from a significantly more stable operating base. The focus now is on accelerating volume growth, improving asset utilization, expanding customer engagement across both APIs and formulations, and converting the strengthened pipeline into commercial scale-up opportunity over the medium term. With that, I hand over to Amrit.

Okay. So, I'm starting from Specialty Chemical. So, Specialty Chemical reported revenue of $2.913 billion in FY26. A marginal decline of 2.1% year-on-year. The business was impacted by customer program phasing, regulatory timing, and generics pressure. In agrochemical, we continue to work on active ingredient and advanced intermediates. During the year, we saw progress in qualification campaigns, registration sample work, and new lab programs. Engagement continues with large global agrochemical innovators across qualification work, registration sample, and advanced intermediate programs. In the performance chemical business, photochrome coating application remains relatively stable. The OLED business is going through a product cycle transition. We are also seeing early stage engagement in electronic materials and semiconductor linked chemistries. These are still at an evaluation stage and will take time to scale. For FY27, the focus is on converting customer qualifications, RFQs, and confirm orders into revenue. FY27 will be a qualification and readiness year for parts of the portfolio, with supplies expected to build as customer program's progress grows to return in FY28. With that, I will hand it over to Himanshu. Thank you.

Thank you, Amrit, and good evening, everyone. Let me take you through the financial performance. For FI26, revenue stood at $22.68 billion, a decline of approximately 13% year-on-year. The adjusted EBITDA stood at $4.77 billion. EBITDA margin stood at 21%, while our standalone adjusted EBITDA margin were at 24.6%. You for? and FI26 performance were in line with the guidance we had shared last quarter. Gross margin was at 70.8%. This was supported by product mix, backward integration, cost actions, and benefit of INR depreciation. Operating margins were impacted by lower volumes, continued investment in business, and weak performance by subsidies. Towards the end of Q4, uncertainties in the Middle East region led to escalation in logistics and freight cost, along with selective inflation in certain raw materials and key starting materials. While Q4 did not witness any material impact from the situation, Q1 will experience impact of nearly 100 to 150 bps on our FI26 gross margin levels, largely on account of API plus business. We are under discussion with some of our customers to share part of this cost inflation. CapEx during the year was Rs. 2.15 billion. This was focused on ADC, oligonucleotides, manufacturing infrastructure, and our quality systems. We expect CapEx spent of nearly 3 billion in FI27. Free cash generated in FI26 stood at $1.73B. In FI27, growth will return from second half of FI27 onwards. Quarter 1 FI27 is to be low on both revenue and EBITDA, largely on account of revenue schedules skewed towards second half. Escalation in logistics and input cost arising from the Middle East geopolitical situation as well as higher operating cost. Improvement in EBITDA should become visible in the second half as the volumes recover, order conversion improves, and product mix normalizes. We believe the business is moving towards a bottoming out phase, with quarter 1 FI27 to be the low point. We expect recovery becoming more visible from second half of FI27, supported by execution on existing programs, customer conversions, reloads, and improving utilization across the platform. With that, I'll hand it back to Cinderella.

Thank you, Hamanju. We will now open the floor for question and answers.

Thank you very much. Ladies and gentlemen, we will now begin the question and answer session. Anyone who wishes to ask a question may press star and 1 on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and 2. Participants are requested to please use handsets while asking a question. We will now wait for a moment while the question queue assembles. Our first question is from the line of Karthi from Suyash Advisors. Please go ahead.

Yeah, good evening, gentlemen. Mr. Omang, welcome to Kohans. If this talk is any indication, your present is greatly appreciated. So I had just a couple of clarifications. One is if you could... For FY26, that is, split the CDMO revenues into ADCs, small molecules, for Sapala and NJ, and give an outlook for 27 and beyond. And a detail to that would be, what is the contribution expected from the two products, which saw a big drawdown last year, and what would be the likely contribution from the two new products, which have been more commercialized.

Sergeant, I'm going to talk about this. Karthi, sorry about that. I'll answer part of the question and then I'll hand it over to Man. So from the contribution of the two large molecules, commercial molecules that we've seen destalking, as communicated earlier, the impact is around 260 crores.

Yes, I said how much of that is likely to return in FY27. And the two new products, what could be the likely contribution? That was my question.

So, from our return, we are in active discussion with both the customers, and we expect there would be a return in both these molecules. However, you will have to allow us to have meaningful conversations, crystallize these orders, before we communicate to you on the actual amount. On the new products, sorry, please.

Yeah, you're saying there is no visibility as on date. That's what I am to take away, right?

No, what I'm saying right now to you is there is a visibility because we are in conversations with the customers. What I cannot confirm to you is the value at this stage. But I can confirm to you that we are expecting both these molecules to return back to us in FY27.

Yeah, and you were talking about the other two new products added to the commercial portfolio.

I'll ask Sian to contribute and answer that.

So, with regard to the two new products that have been approved, as indicated in my speech, we have received four commercial orders for four key-starting materials. With regard to one of the commercial drug, that's a revenue that will appear mostly in Q2, FY27, and in Q3, FY27. With regard to the second product that has been approved, we are in active discussion in order to determine when those will be delivered.

Sure. And would you be able to call out the contribution of ADC to your CDMO revenue this year, FY26, that is, and what is the likely growth in FY27?

I think we are not providing that color right now, but as we reassess the strategy, maybe a few months later we could consider that. But at this point, we are not providing that color.

Sure. And one last thing before I get back in the queue, sir. Would you be able to provide the breakup of the one-time expenses over the last two years, roughly about 109 crore rupees? Can you break that down so we have a clear understanding of the nature of these one-offs?

He wants to know the breakdown. Maybe you can just tell him this year.

So I'll tell you about this year. I think this year on our one-time expenses, there are two large elements. One is that we have taken a one-off inventory provision, which is around 195 million, and we've also provided for Certain customer adjustments, that's in the range of around 126 million. On to the point of ADC and Oligo, we've called out in the presentation that our NISTEC as a percentage of revenue is 16.2% for the full year.

Sure. Thanks and thank you, sir.

Thank you. Ladies and gentlemen, to ask a question, you may please press star, then one. Our next question is from the line of Shyam Srinivasan from Goldman Sachs. Please go ahead.

Yeah, thank you for taking my question, and good evening, team, and welcome, Oman. So, I think first question is just on, you know, from a forward-looking perspective, I think I've seen the guidance that has been mentioned on the opening remarks and being listed presentation. Q1 is supposed to be weak and second-half recovery. So, just if you could share other than the base effect, is there anything tangible or qualitative that you could add? And if you could also give color across the three segments as well, Spectrum, API Plus, and CDM, at least.

So, Shyam, this is Himanshu. See, at this stage, as we have said, that the second half would be when we would see the growth returning, right? And the first half is weak, with COS-01 in particular, weak with both revenue and EBITDA. We do expect that there would be... I mean, in the order of revenue, it would be API followed by CDMO and followed by spec chem. That would be the order. But I would not be able to give you more dimension on it. But that's essentially what we are looking at. So quarter one would be low. The quarter two is our understanding where we expect the quarter two to be stable. And then H2 is where we are calling out growth moving forward.

Thank you, Humanshu. Just second question to Humanshu, from your own vantage point, you've spent so much time in the pharma industry. Sir, what are some of the things that you've, I know it's been a short time since you've been at Kohans, but just want to understand, you know, just to double click on your role and what are some of the best practices you think you would like to bring or if it's just enhancing already existing systems, just some philosophical thoughts around the path forward for Kohans.

Yeah, I think the, I mean, if I was to broadly and again, look, I'm sorry, please don't hold me to it. It's been nine days or 10 days, but it seems to me that Kohans has attentioned significant places or significant portions of the value chain in the ABC oligonucleotide chemistry. And I think there are some... That we will continue to augment and build so as to offer a value offering that is probably unique and maybe more integrated. That's one of the things that we will do. I think there are some chemistries on the small molecule, on the API and the API plus side, which are pretty unique to what, you know, to Bohans does, which are around the areas of colored compounds, around certain types of chemistries, which are. Which are important for Kohans. And I think the intention is to build these further while improving the product offering. So I think basically the capabilities of science, the capabilities of the ability to offer differentiation is what I think Kohans would position itself to do. And linked to that would be operating leverage that hopefully will come out from the business. As we begin to pull, you know, as we begin to get more revenue, and we begin to optimize the type of expenditures that the business has invested in over the past couple of quarters. So I think I see those as important areas to go. It's really about embedding Kohans into the value chain of new drugs, as well as, you know, off patent and unique drugs that exist in our marketplace.

Thank you, sir, and all the best.

Thank you very much.

Thank you. Our next question is from the line of Sajal Kapoor from Antifragile Thinking.

Please go ahead. Yeah, hi. Thank you for taking my questions. Hi, team. Now with Umang on board, and some reshuffling and some rethinking will invariably happen. We just, as shareholders, we look forward to some growth. Can I just clarify that when we say H2, from current fiscal of H2, we will revert back to growth? Will we be measuring ourselves against the previous YOY basis or the FY25, which was the last growth Q3 and Q4 of fiscal 25? Are we benchmarking our growth or expecting that growth to come on that base, the higher base?

Yeah, so Sajid, this is Himanshu.

So first of all, I think the growth would be on a year-on-year basis. Okay. I think that's important for us to relate to, right? Having said that, I'm not saying that there may or may not be a growth versus the previous to previous year. I think what we must understand. And I think I mentioned that to Karthi, that there is a large commercial which got dropped in the Fi26. And as you know, that we are ramping up our commercial. Our phase 3 pipeline, as we have called out, has moved up to 10. And from the 9, it moved to 10 with two molecules moving out into commercial. So we have actually added three molecules into the pipeline. So the commercial gets strengthened. However, it does take time for the commercial to improve or for the innovators to make these products commercial. And therefore, we would see a lag effect on the revenue. And that's essentially what we are looking at from our business perspective.

Now, that's helpful. And if I could just conclude with my second question, I mean, what is likely to be the hardest decision for you as a team you will need to make at Kohens in the next 18 to 12 months? Because, see, ours is a regulated business. It's a relationship-based business where trust compounds over many years with our customers. So, in that context, What do you think is the biggest priority for the team to sort of rebuild that confidence, both with the regulators and the customers, so that when we get back to growth, we stay in growth mode for a very long period? Thank you.

I think I can think of two things, or maybe three. Let me put out three things here. One is the operational rigor. When we have the green light to go, we can't be short of capacities, we can't be short of product robustness, and the quality systems have to be strong. The second point is customer relationships have to deepen, and like Kimanshu was mentioning, there are some... Places where we're beginning to see diversified customer base and diversified customer orders coming in versus our historical reliance on one or two customers. And I think the third is just the science engine. We need to keep progressing our science engine, whether it's in the area of ADCs and oligonucleotides and other hematite chemistries, to even beyond into regular solid dose. Chemistry and solid dose capabilities. So I think pushing the science envelope, which means talent, pushing our quality envelope and the robustness of our offering, right, as well as pushing the ability to create and sustain long term relationships. I think those are the three things around which I think we will be making decisions going forward. I don't know if we're at a point where we will make tough decisions. At this stage, but wherever a tough decision is needed on where we allocate capital, it's likely to be in these three areas.

Thank you.

Thank you, Umang. I wish you a very long and productive career here at Kohen. Thank you so much. Thank you. Thank you so much.

Thank you. Our next question is from the line of Sithat Negandhi with CWC. Please go ahead.

Thanks for the opportunity. Umang, you just mentioned about a certain program concentration. If you could share the program and customer concentration in revenue for each of the three segments. The second would be any specific examples of AI implementation that you are seeing, which is enabling you either to get, you know, Better quality output or get output faster, especially in the later stages of your programs. And lastly, if you could share any color on the FI27 guidance in terms of what growth can one expect. And I hear you on the H1, H2, please.

Jan, you'll take the person. So, let me clarify.

Could you repeat the question on the customer concentration?

So, could you share your customer concentration for the CDMO segment by program or molecule and by customer? So, what's the revenue salience of the top one, top three, and top five customers, top one, top three, and top five molecules?

So, I mean, we don't give these level of details. Nevertheless, I mean, I can answer some of the questions on customer concentration, right? And you can see that in our results, right? So we have had, by the past, reliance on a few molecules, right? Historically, and that's the reason why we are in the situation we are in today, especially on the small-molecule side of the business, of the CDMO business. This concentration is changing positively year-on-year, meaning that there is less... There will be less concentration in FY26 than there was in FY25, and there will be less concentration in FY27 versus FY26 as we continue to develop our customer project pipeline. And that's essentially the message.

That's one way to de-risk long term. I hand over to Gunjan for the same question, I think.

And the API Plus case, which is, you know, a product business, our top 15 products contribute nearly half of the API revenues there. If I give you a favor around the kind of customers, so nearly two-thirds of the revenues come from customers who are innovators or large global generic or regional leaders in the generic space, and only, you know, nearly one-third is with smaller customers there.

You got it.

And any FI27 guidance and any specific AI implementation that is helping you either get through programs faster or get better quality output for any of your programs?

I mean, maybe I can answer. This is Jan here on the AI-related topic, right? What's important for us is customer-centricity and how we support our clients in their projects. That's how we are successful as an organization. As such, we've implemented some AI tools in order to improve our analysis on essentially our results, right, in order to be able to have proper communication with clients and offer as well opportunities for improvement. So that's one example of use of AI tools that we currently have in our platform to support the client.

And I'll just add a couple of points here. On the AI use, we are in active discussions and evaluating some tools around which can help improve operational efficiencies and can also support us on the regulatory aspects in terms of reducing our time to file and improve the quality of filings. That's the limited use that we are. Additionally, we are also exploring, you know, the creation of data lakes and the databases that can help, you know, take better and faster decisions going forward, both on operational as well as customer side.

Any FI27 guidance across the three years?

Sudhat, this is Himanshu. And yes, we really appreciate the need to give a guidance, but I think you would have to allow us some time to come back and give guidance. At this stage, I think we are comfortable to share that the growth will return from second half, and quarter two would be stable, while quarter one is a weak quarter, both on revenue and EBITDA.

Thank you.

Thank you. Our next question is on the line of Ashish from UTI. Please go ahead.

Yeah, thanks for the opportunity. So given that, you know, between the standard and the console, there's a difference in the margins. So I wanted to have some details on Sephora and NGA Bio. What is the projected timeline for consolidated margins to return to the historical benchmark of 30%? So if you could use some color around this would be helpful.

So, Ashish, this is Ivanchu.

So, I mean, at this stage, one, the results will enable you to get a sense and a precision of how the standalone and the subsidiary results are, right? So, that would give you a good indication of the 4% to 5% play that we are looking at it. And I think there is. There is a recognition that is there. We've called out that Sapala has a reload on phase two, phase three, and that could kind of help the Sapala business accelerate from here onwards. On NJBIO, there is work being progressed with NJBIO team in terms of bringing the business back. To profitability. But as I said, we do need some time to kind of come back to all of you on how this would shape up in the coming year. And maybe I'll ask Jan to further contribute on the subject.

So, on the NG Bayou situation, right? We have a very important investment that is currently being implemented to be able to support the bioconjugation program to phase one, phase two. So this is where a lot of the value moving forward is. As such, I mean, it takes always some time here because it takes about one year to implement plus some time for validation and then... Being able to execute all the different programs here. So give us here a little bit more than two years to get back to this loop.

Okay, this is helpful.

Lastly, since you said recovery, the order of recovery would be API first, I just wanted to understand the second half recovery that you mentioned. Is that dependent a lot on the API segment recovery? And to that extent, what I was trying to understand is the NACHARAM. So, what's the kind of dependency that we have when we say it would be a second-hour recovery?

I think what I mentioned to Shyam was how we were looking at the H1. When you're looking at recovery from an H2 perspective, we expect the CDMO business to have an accelerated recovery. And in fact, all the three businesses, we expect the recovery to be strong in the second half. So it's just that the order book is skewed towards the second half, which is why we are looking at weak quarter one and stable quarter two.

Yeah, this helps. Thanks a lot.

Thank you. Our next question is from the line of Shreya Chatterjee with Ageless Capital. Please go ahead.

Thank you for taking my question. My first question is just confirming the fact that you had mentioned that there would be four commercial molecule launch in FI27. So, I guess two molecules have already launched. So, is that in progress, like four total molecules to be launched in FI26 and FI27? Hello.

Yep.

So, I confirmed, right, two have launches, and we expect, have launched, right, when we expect the two others to launch, of course, depending on the clinical performance, and we expect these to be known within the next 12 to 18 months.

And would it be possible to give any color, like in H2, how much are you expecting from this new commercial molecule launch?

I mean, I think Imanchu had provided already the response. I mean, we are not yet ready to answer that question. That will come later.

Got it. And also on the new pH 3 molecule that you have added on the small molecule side and the ADC molecule that you had commercialized, will it be possible to give some color to these two molecules?

I mean, this is the end again.

Phase three, we normally don't provide too much color, right? This is early phase three, so we need a little bit more time. Even the client might not know himself, right, the kind of volume that is expected here.

Got it. And also, if it's possible, like this question is to Himanshu, to provide the breakdown of other expenses for the full year, which is like a big amount, 671 crores, if that's possible, like where the major expenses heads going, a rough breakdown of that amount, it would be helpful.

Share, I mean, the financials have been declared. And they have the necessary state from that perspective. I mean, I am not sure what additional flavor you are seeking. If you can help me, then what is possible, we will certainly want to share.

Like, what are the major heads of the expenses under other expenses, which is like a big amount, 671 goes. Because our gross margin seems to be quite high, but when we convert it to adjust to EBITDA margin, we're losing out a lot. One part is employee benefit expenses, but then other expenses is also big. So just trying to understand what are the major expenses currently in FI26.

So there is...

Under other expenses.

Yes, so large portion of that is the conversion expenditure. That's almost in the range of 400 plus crores. And then the balance 260 is a function of the marketing expenditure. As you know that we had a merger and therefore we were building the brand. So brand building expenditure as well as the entire SG&A. Actually the entire SG&A if you look at it. Whether it's the office expenditure, travel expenditure, these are all grander expenditure,

which is typically there in the business.

Got it. Got it. Thank you. Thank you.

Thank you. Ladies and gentlemen, to ask a question, you may please press star and one. Our next question is from the line of Chirag Shah from White Pine Investment Management, Private Limited. Please go ahead.

Thanks a lot for the opportunity.

I have two questions. Question one on some indication on the vacuum that has got created because of loss of two molecules. So, Jan, specifically for you, what is being done right now to ensure this kind of vacuum doesn't get created in future? So, that's question one. I have a second question I ask once you respond. It's for Umang. The second question is for actually Umang.

So, thank you for the question, right?

And that's true. We mentioned it several times. I mean, we have a dip because of the high concentration in a few molecules and the fact that some are getting close to becoming generics, right? So what do we do about it in order to bring growth is essentially expansion in terms of number of customers. And being able to get projects that are later phase in the customer project pipeline to accelerate recovery. So that's what we are doing at the moment. We see good traction with a strong funnel that has been multiplied by two, essentially, in the last six months with regard to small molecules that give us a strong hope that we are going in the right direction.

Okay. And second question for Umang, actually a slightly different question. Since you have joined the organization, have you been able to focus on corporate governance and strengthening the processes? Or it has not been on your agenda as of now? Why I'm asking that in your absence, when you are not there, it's coincidental that certain information and certain investor category have co-aligned in that sense. At the peak, some information has got out and some investors have exit and have re-entered at the bottom of the stock price. And since then, the again positive announcement has started. So, it's a request if you look at the centering of corporate governance slash information flow, which I believe was happening selectively. I could be absolutely wrong, and I hope I am wrong. So, if you have not been able to spend time, I would request you to focus on that. That's my second question.

No, certainly. I think as part of this role, the governance requirement is paramount, and I will be spending time on that as well in the next few months. But thank you for raising this.

And I hope you will be able to update us whenever you can, maybe two quarters down the line on what changes have you made on this site.

Yes, absolutely.

Thank you very much.

Thank you. Thank you. Our next question is from the line of Siddharth Nagandhi with CWC. Please go ahead.

Just a follow-up, on the claim that you put in respect of the one-time settlement with the customer, if you could give some color on what that was towards and does that have any impact or bearing on that customer relationship and therefore the revenue, likely revenue impact going forward, that was one question. And on the brand building expenses that were there, therefore, do we expect those also to be more one-time in nature and therefore some cost savings on that? In FI 27 and going forward, that's question two. Question three is, if you could give us a little bit of a breakup on, you know, the number of programs that you have underway and break down by phase into amniotoza, phase one, phase two, phase three, and commercial.

So, Siddharth, on your first point,

I think the customer settlement is purely commercial, and therefore, given the nature of the settlement, we don't see any impact on the revenue or on the relationship with the customers. On the second question, yes, we would see a reduction in the marketing expenses, given that a part of the brand building has already been done. So, to that extent, your observation is right. And could you quantify that?

Sorry, I'm interjecting. Could you quantify that?

No, I would not prefer to quantify that at this stage. I mean, we do not give specific categories of expenditure. But yes, there would be a reduction that would happen on that. And on your third question, I'm going to request Jan to address that.

So, I think we thank you, Emanshu, on the programs. I think we communicate on the phase three and commercial programs quite extensively. It's part of the portal as well, right? So, I think this information is available. What I can tell you as well... The quality of the programs that we are onboarding right now in Phase 1, Phase 2 is also pretty strong, with some clients also asking us to produce the API or the complex molecules for them. So that's good news. I mean, of course, it's Phase 1, Phase 2. It takes some time to develop, but that shows as well the

strength of the other platform.

Thank you.

Thank you.

Ladies and gentlemen, we will take that as a last question for today. I would now like to hand the conference over to the management for closing comments.

Thank you, everyone, for your time and joining us today. See you next time on the photo and call.

Thank you. On behalf of Kohans Life Sciences Limited, that concludes this conference. Thank you all for joining us. You may now disconnect your lines.